JP2004533449A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004533449A5 JP2004533449A5 JP2002589043A JP2002589043A JP2004533449A5 JP 2004533449 A5 JP2004533449 A5 JP 2004533449A5 JP 2002589043 A JP2002589043 A JP 2002589043A JP 2002589043 A JP2002589043 A JP 2002589043A JP 2004533449 A5 JP2004533449 A5 JP 2004533449A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- cancer
- cell
- antibody
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 52
- 210000004027 cell Anatomy 0.000 claims 33
- 206010028980 Neoplasm Diseases 0.000 claims 23
- 201000011510 cancer Diseases 0.000 claims 21
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 claims 13
- 101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 claims 13
- 239000003795 chemical substances by application Substances 0.000 claims 8
- 206010042971 T-cell lymphoma Diseases 0.000 claims 7
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 7
- 210000001744 T-lymphocyte Anatomy 0.000 claims 5
- 210000003719 b-lymphocyte Anatomy 0.000 claims 5
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 4
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 4
- 239000002246 antineoplastic agent Substances 0.000 claims 4
- 239000003124 biologic agent Substances 0.000 claims 4
- 229940127089 cytotoxic agent Drugs 0.000 claims 4
- 239000002532 enzyme inhibitor Substances 0.000 claims 4
- 229940125532 enzyme inhibitor Drugs 0.000 claims 4
- 201000002510 thyroid cancer Diseases 0.000 claims 4
- 208000003950 B-cell lymphoma Diseases 0.000 claims 3
- -1 radionuclide Substances 0.000 claims 3
- 230000002792 vascular Effects 0.000 claims 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims 2
- 229940080778 Adenosine deaminase inhibitor Drugs 0.000 claims 2
- 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 claims 2
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010005949 Bone cancer Diseases 0.000 claims 2
- 208000018084 Bone neoplasm Diseases 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 102000019034 Chemokines Human genes 0.000 claims 2
- 108010012236 Chemokines Proteins 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 229940124213 Dipeptidyl peptidase 4 (DPP IV) inhibitor Drugs 0.000 claims 2
- 241000598436 Human T-cell lymphotropic virus Species 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 208000027190 Peripheral T-cell lymphomas Diseases 0.000 claims 2
- 208000033759 Prolymphocytic T-Cell Leukemia Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 claims 2
- 206010042970 T-cell chronic lymphocytic leukaemia Diseases 0.000 claims 2
- 208000000389 T-cell leukemia Diseases 0.000 claims 2
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 claims 2
- 208000026651 T-cell prolymphocytic leukemia Diseases 0.000 claims 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 2
- 206010057644 Testis cancer Diseases 0.000 claims 2
- 208000033781 Thyroid carcinoma Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 2
- 239000002487 adenosine deaminase inhibitor Substances 0.000 claims 2
- 201000006966 adult T-cell leukemia Diseases 0.000 claims 2
- 230000022131 cell cycle Effects 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 239000002872 contrast media Substances 0.000 claims 2
- 239000003603 dipeptidyl peptidase IV inhibitor Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 230000002489 hematologic effect Effects 0.000 claims 2
- 210000004408 hybridoma Anatomy 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 210000002751 lymph Anatomy 0.000 claims 2
- 201000011649 lymphoblastic lymphoma Diseases 0.000 claims 2
- 210000004698 lymphocyte Anatomy 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 206010038038 rectal cancer Diseases 0.000 claims 2
- 201000001275 rectum cancer Diseases 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 201000003120 testicular cancer Diseases 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 208000013077 thyroid gland carcinoma Diseases 0.000 claims 2
- 239000003053 toxin Substances 0.000 claims 2
- 231100000765 toxin Toxicity 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 206010046766 uterine cancer Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 230000008512 biological response Effects 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 230000002500 effect on skin Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 229940079322 interferon Drugs 0.000 claims 1
- 238000001361 intraarterial administration Methods 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000007913 intrathecal administration Methods 0.000 claims 1
- 230000002601 intratumoral effect Effects 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000003607 modifier Substances 0.000 claims 1
- 230000017074 necrotic cell death Effects 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 201000001282 rectum sarcoma Diseases 0.000 claims 1
- 201000006845 reticulosarcoma Diseases 0.000 claims 1
- 208000029922 reticulum cell sarcoma Diseases 0.000 claims 1
- 150000004492 retinoid derivatives Chemical class 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 230000005740 tumor formation Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29053101P | 2001-05-11 | 2001-05-11 | |
| PCT/US2002/014462 WO2002092127A1 (en) | 2001-05-11 | 2002-05-08 | Anti-cd26 monoclonal antibodies as therapy for diseases associated with cells expressing cd26 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004533449A JP2004533449A (ja) | 2004-11-04 |
| JP2004533449A5 true JP2004533449A5 (enExample) | 2005-12-22 |
Family
ID=23116424
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002589043A Pending JP2004533449A (ja) | 2001-05-11 | 2002-05-08 | Ｃｄ２６を発現している細胞に関連する疾患の治療としての抗ｃｄ２６モノクローナル抗体 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US7198788B2 (enExample) |
| EP (1) | EP1392361A4 (enExample) |
| JP (1) | JP2004533449A (enExample) |
| KR (1) | KR100863624B1 (enExample) |
| CN (2) | CN101172158A (enExample) |
| AU (1) | AU2002308637B2 (enExample) |
| CA (1) | CA2446806A1 (enExample) |
| WO (1) | WO2002092127A1 (enExample) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2344653A1 (en) * | 1998-09-29 | 2000-04-06 | Gamida Cell Ltd. | Methods of controlling proliferation and differentiation of stem and progenitor cells |
| IL152904A0 (en) * | 2002-01-24 | 2003-06-24 | Gamida Cell Ltd | Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations |
| EP1465982A4 (en) * | 2002-01-25 | 2006-06-07 | Gamida Cell Ltd | PROCESS FOR EXPANSION OF STEM AND PRESERVATIVE CELLS AND EXPANDED CELL POPULATIONS THEREWITH OBTAINED |
| CA2479679A1 (en) * | 2002-03-18 | 2003-09-25 | Gamida-Cell Ltd. | Methods of inducing differentiation in ex vivo expanded stem cells |
| JP4596916B2 (ja) * | 2002-09-05 | 2010-12-15 | メディミューン，エルエルシー | Ｃｄ２拮抗薬を投与することによりｔ細胞悪性腫瘍を予防または治療する方法 |
| US20050054097A1 (en) * | 2002-11-17 | 2005-03-10 | Tony Peled | EX-VIVO expansion of hematopoietic system cell populations in mononuclear cell cultures |
| JP5717937B2 (ja) * | 2002-12-06 | 2015-05-13 | ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | プロテアソーム阻害療法を用いた患者の同定、判定および治療方法 |
| US20040202666A1 (en) * | 2003-01-24 | 2004-10-14 | Immunomedics, Inc. | Anti-cancer anthracycline drug-antibody conjugates |
| US7550590B2 (en) | 2003-03-25 | 2009-06-23 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| JP2007511467A (ja) | 2003-05-14 | 2007-05-10 | タケダ サン ディエゴ インコーポレイテッド | ジペプチジルペプチダーゼインヒビター |
| CN1816356A (zh) | 2003-05-14 | 2006-08-09 | 免疫原公司 | 药物缀合物组合物 |
| WO2005016911A1 (en) | 2003-08-13 | 2005-02-24 | Takeda Pharmaceutical Company Limited | 4-pyrimidone derivatives and their use as peptidyl peptidase inhibitors |
| WO2006030442A2 (en) * | 2004-09-16 | 2006-03-23 | Gamida-Cell Ltd. | Methods of ex vivo progenitor and stem cell expansion by co-culture with mesenchymal cells |
| CA2597407C (en) | 2005-02-11 | 2013-09-10 | Immunogen, Inc. | Process for preparing stable drug conjugates |
| BRPI0613770A2 (pt) * | 2005-07-22 | 2009-05-19 | Y S Therapeutics Co Ltd | anticorpos anti-cd26 e métodos de uso destes |
| AU2006278573A1 (en) | 2005-08-03 | 2007-02-15 | Immunogen, Inc. | Immunoconjugate formulations |
| NZ595430A (en) | 2005-08-24 | 2013-05-31 | Immunogen Inc | Process for preparing maytansinoid antibody conjugates |
| WO2007033350A1 (en) | 2005-09-14 | 2007-03-22 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors for treating diabetes |
| EP1924567B1 (en) | 2005-09-16 | 2012-08-22 | Takeda Pharmaceutical Company Limited | Process for the preparation of pyrimidinedione derivatives |
| US20090162405A1 (en) * | 2006-12-14 | 2009-06-25 | Yong Qian | Proteinase-engineered cancer vaccine induces immune responses to prevent cancer and to systemically kill cancer cells |
| US8846393B2 (en) | 2005-11-29 | 2014-09-30 | Gamida-Cell Ltd. | Methods of improving stem cell homing and engraftment |
| TW200838536A (en) | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
| KR101334934B1 (ko) * | 2006-12-27 | 2013-11-29 | 삼성디스플레이 주식회사 | 유기발광표시장치의 에이징 방법 |
| CA2680368A1 (en) * | 2007-03-14 | 2008-09-25 | The University Of Tokyo | A method of treating malignant mesothelioma |
| KR200450480Y1 (ko) * | 2008-09-22 | 2010-10-07 | 대우조선해양 주식회사 | 앵글 취부장치 |
| WO2010099918A1 (en) * | 2009-03-06 | 2010-09-10 | Klaus Tschira Stiftung Ggmbh | Pharmaceutical composition and method for identifying a cancerous and/or an inflammatory disease in a patient |
| WO2010141566A1 (en) | 2009-06-03 | 2010-12-09 | Immunogen, Inc. | Conjugation methods |
| US8321012B2 (en) * | 2009-12-22 | 2012-11-27 | The Invention Science Fund I, Llc | Device, method, and system for neural modulation as vaccine adjuvant in a vertebrate subject |
| CN102781316B (zh) * | 2010-03-01 | 2016-07-06 | 陶制药有限责任公司 | 癌症诊断和成像 |
| JPWO2011118804A1 (ja) * | 2010-03-26 | 2013-07-04 | 国立大学法人徳島大学 | 新規抗ｃｄ９８抗体とその用途 |
| RS58367B1 (sr) | 2011-03-29 | 2019-03-29 | Immunogen Inc | Priprema konjugata antitela i majtanzinoida jednostepenim postupkom |
| AU2013216863B2 (en) * | 2012-02-10 | 2018-09-06 | Seagen Inc. | Detection and treatment of CD30+ cancers |
| JP6348848B2 (ja) | 2012-02-13 | 2018-06-27 | ガミダ セル リミテッド | 間葉系幹細胞の増殖 |
| US9567569B2 (en) | 2012-07-23 | 2017-02-14 | Gamida Cell Ltd. | Methods of culturing and expanding mesenchymal stem cells |
| US9175266B2 (en) | 2012-07-23 | 2015-11-03 | Gamida Cell Ltd. | Enhancement of natural killer (NK) cell proliferation and activity |
| IN2015DN03202A (enExample) | 2012-10-04 | 2015-10-02 | Immunogen Inc | |
| EP2767549A1 (en) | 2013-02-19 | 2014-08-20 | Adienne S.A. | Anti-CD26 antibodies and uses thereof |
| US11242399B2 (en) | 2013-02-19 | 2022-02-08 | Adienne S.A. | Anti-CD26 antibodies |
| CN107417691B (zh) * | 2013-03-15 | 2020-06-26 | G1治疗公司 | 高效的抗赘生剂和抗增生剂 |
| US9464092B2 (en) | 2013-03-15 | 2016-10-11 | G1 Therapeutics, Inc. | Transient protection of normal cells during chemotherapy |
| JP2015030666A (ja) | 2013-07-31 | 2015-02-16 | 学校法人順天堂 | 抗ヒトｃｄ２６モノクローナル抗体又はその抗原結合性断片 |
| CN103694352B (zh) * | 2013-12-19 | 2015-12-09 | 江苏众红生物工程创药研究院有限公司 | 一种抗 cd26 抗体及其制备方法 |
| CN103709251B (zh) * | 2013-12-19 | 2016-04-13 | 江苏众红生物工程创药研究院有限公司 | 全人源抗cd26抗体及其应用 |
| TWI677505B (zh) * | 2014-08-18 | 2019-11-21 | 瑞士商艾迪安納股份有限公司 | 抗ｃｄ２６抗體及其用途 |
| EP3191098A4 (en) | 2014-09-12 | 2018-04-25 | G1 Therapeutics, Inc. | Combinations and dosing regimes to treat rb-positive tumors |
| WO2016040848A1 (en) | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors |
| CN107406463A (zh) | 2014-12-04 | 2017-11-28 | 细胞基因公司 | 生物分子共轭物 |
| WO2016112261A2 (en) * | 2015-01-09 | 2016-07-14 | Medimmune, Llc | Assay to detect human dpp-4 |
| SG11201802915WA (en) * | 2015-09-11 | 2018-05-30 | Ys Ac Co Ltd | Cancer treatment composition combining anti-cd26 antibody and other anticancer agent |
| JP2019501139A (ja) | 2015-11-25 | 2019-01-17 | イミュノジェン・インコーポレーテッド | 医薬製剤及びその使用 |
| WO2017189526A1 (en) * | 2016-04-25 | 2017-11-02 | Musc Foundation For Research Development | Activated cd26-high immune cells and cd26-negative immune cells and uses thereof |
| AU2018392227B2 (en) * | 2017-12-22 | 2025-05-01 | Adienne S.A. | Quantitative cellular method for determining the biological activity of an anti-CD26 ligand |
| CN109709337B (zh) * | 2018-12-28 | 2021-09-14 | 江苏众红生物工程创药研究院有限公司 | 人cd26的免疫组化检测试剂盒及其临床应用 |
| CN109535255B (zh) * | 2018-12-28 | 2020-10-27 | 江苏众红生物工程创药研究院有限公司 | 一种抗人cd26抗体及其在检测试剂盒中的应用 |
| WO2020236890A1 (en) * | 2019-05-20 | 2020-11-26 | Mayo Foundation For Medical Education And Research | Treating chronic liver disease |
| CA3155930A1 (en) * | 2019-09-27 | 2021-04-01 | Starkage Therapeutics | Senescent cell-associated antigen-binding domains, antibodies and chimeric antigen receptors comprising the same, and uses thereof |
| US11723926B2 (en) | 2019-09-27 | 2023-08-15 | Starkage Therapeutics | Senescent cell-associated antigen-binding domains, antibodies and chimeric antigen receptors comprising the same, and uses thereof |
| US10988479B1 (en) | 2020-06-15 | 2021-04-27 | G1 Therapeutics, Inc. | Morphic forms of trilaciclib and methods of manufacture thereof |
| WO2022220232A1 (ja) * | 2021-04-12 | 2022-10-20 | 国立大学法人 東京大学 | すい臓がん検出用蛍光プローブ |
| BR112023022312A2 (pt) | 2021-05-13 | 2023-12-26 | Adienne S A | Métodos de tratamento de dermatomiosite |
| IL308373A (en) | 2021-05-13 | 2024-01-01 | Adienne S A | Methods for treating graft versus host disease |
| CN116023491A (zh) * | 2021-10-25 | 2023-04-28 | 江苏众红生物工程创药研究院有限公司 | 抗cd26抗体及其应用 |
| CN116549629A (zh) * | 2022-01-30 | 2023-08-08 | 江苏众红生物工程创药研究院有限公司 | Cd45作为生物标志物在筛查cd26抗体或其衍生物治疗肿瘤有效性和精准性中的应用 |
| CN114878820A (zh) * | 2022-05-30 | 2022-08-09 | 湛江中心人民医院 | 肺腺癌病理诊断标志物及其应用 |
| WO2025027529A1 (en) | 2023-07-31 | 2025-02-06 | Advesya | Anti-il-1rap antibody drug conjugates and methods of use thereof |
| CN117568477B (zh) * | 2023-10-17 | 2024-11-19 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | Dpp4作为nk/t细胞淋巴瘤肿瘤标志物的应用 |
| TW202530255A (zh) | 2023-12-15 | 2025-08-01 | 法商亞維西亞有限公司 | 抗ｉｌ－１ｒａｐ結合結構域及其抗體－藥物偶聯物 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5120642A (en) * | 1989-11-28 | 1992-06-09 | Coulter Corporation | Monoclonal antibody which distinguishes helper inducer and suppressor inducer cd4+ lymphocytes |
| US5863904A (en) | 1995-09-26 | 1999-01-26 | The University Of Michigan | Methods for treating cancers and restenosis with P21 |
| US6951924B2 (en) * | 1997-03-14 | 2005-10-04 | Human Genome Sciences, Inc. | Antibodies against secreted protein HTEBYII |
| US6573096B1 (en) * | 2000-04-01 | 2003-06-03 | The Research Foundation At State University Of New York | Compositions and methods for inhibition of cancer invasion and angiogenesis |
| AU2001269123A1 (en) * | 2000-07-10 | 2002-01-21 | Bayer Aktiengesellschaft | Regulation of human dipeptidyl-peptidase iv-like enzyme |
| IL155245A0 (en) * | 2000-10-12 | 2003-11-23 | Ferring Bv | Novel serine protease genes related to dppiv |
-
2002
- 2002-05-08 WO PCT/US2002/014462 patent/WO2002092127A1/en not_active Ceased
- 2002-05-08 CA CA002446806A patent/CA2446806A1/en not_active Abandoned
- 2002-05-08 EP EP02769684A patent/EP1392361A4/en not_active Withdrawn
- 2002-05-08 CN CNA2007101410677A patent/CN101172158A/zh active Pending
- 2002-05-08 AU AU2002308637A patent/AU2002308637B2/en not_active Ceased
- 2002-05-08 JP JP2002589043A patent/JP2004533449A/ja active Pending
- 2002-05-08 CN CNB028117077A patent/CN100341572C/zh not_active Expired - Fee Related
- 2002-05-08 KR KR1020037014644A patent/KR100863624B1/ko not_active Expired - Fee Related
- 2002-05-10 US US10/143,553 patent/US7198788B2/en not_active Expired - Lifetime
-
2007
- 2007-02-16 US US11/676,164 patent/US7658923B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004533449A5 (enExample) | ||
| Yoshimura | The chemokine MCP-1 (CCL2) in the host interaction with cancer: a foe or ally? | |
| Robinson et al. | A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era | |
| Schmohl et al. | Engineering of anti-CD133 trispecific molecule capable of inducing NK expansion and driving antibody-dependent cell-mediated cytotoxicity | |
| JP2023030083A (ja) | 治療用ｒｎａ | |
| JP4494977B2 (ja) | Ｇｄ２に結合するマウス１４．１８抗体のヒト化抗体（ｈ１４．１８）およびそのｉｌ−２融合タンパク質 | |
| TW213486B (enExample) | ||
| AU2017278193B9 (en) | Anti-GITR antibodies and uses thereof | |
| Angelot-Delettre et al. | In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent | |
| WO2019129053A1 (zh) | 以抗体Fc区为骨架的融合蛋白二聚体及其应用 | |
| JP2007512243A5 (enExample) | ||
| RU2007133108A (ru) | АНТИТЕЛА, СВЯЗЫВАЮЩИЕСЯ С EphA2, И МЕТОДЫ ИХ ИСПОЛЬЗОВАНИЯ | |
| JP2005514409A (ja) | Ｍｕｃ１８抗原に対する抗体の使用 | |
| IL310938A (en) | Anti-CCR8 antibodies and their uses | |
| Weinreich et al. | Effect of interleukin 1 receptor antagonist gene transduction on human melanoma xenografts in nude mice | |
| CN104968684A (zh) | 新的抗体片段、组合物和其用途 | |
| Balkwill | Cytokines—soluble factors in immune responses | |
| CN118290584A (zh) | 一种包括nk细胞的药物组合物及其在制备治疗肿瘤药物中的应用 | |
| Qi et al. | A novel diphtheria toxin‐based bivalent human EGF fusion toxin for treatment of head and neck squamous cell carcinoma | |
| Sharifi et al. | Generation of human interferon gamma and tumor Necrosis factor alpha chimeric TNT-3 fusion proteins | |
| JPWO2023288241A5 (enExample) | ||
| JPWO2023020621A5 (enExample) | ||
| CN1124284C (zh) | 高效广谱抑制肿瘤生长和转移的新型抗体 | |
| Kuroda et al. | Prostaglandin F2 receptor negative regulator as a potential target for chimeric antigen receptor-T cell therapy for glioblastoma | |
| IL314851A (en) | Combinations of checkpoint inhibitors and oncolytic virus for treating cancer |